This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00179906%3A_____%2F12%3A10125172%21RIV13-MZ0-00179906/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00179906%3A_____%2F12%3A10125172%21RIV13-MZ0-00179906
rdf:type
n6:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.5507/bp.2012.100
dcterms:description
Aims. To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment. Methods. Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period. Results. At the time of assessment 750 entries (750 treated eyes, 725 treated patients) had follow-up longer than 12 months. A treatment change required 7.7 % subjects treated with ranibizumab, 20.5 % with pegaptanib and 22 % with PDT and verteporfin. Average BCVA of all patients at the beginning of primary treatment was 50.7 +- 3 letters and 43 +- 3.5 letters in 12th month (P<0.001). The mean decrease in BCVA was 7.7 +- 0.6 letters during the first 6 months of observation. During the next 6 months, no significant change occurred. The change of primary therapy was required on average after 6.5 +- 2.1 months. Conclusion. BCVA los was the most significantly decelerated in patients who received ranibizumab as a secondary therapy following unsuccessful treatment with pegaptanib sodium. Aims. To determine the effectiveness of second line treatments in patients with neovascular AMD who did not respond adequately to primary treatment. Methods. Retrospective, multicentre assessment. The frequency of primary treatment failure and outcomes of subsequent secondary treatment were assessed according to the type of primary treatment, type of CNV and change in BCVA over a 12 month period. Results. At the time of assessment 750 entries (750 treated eyes, 725 treated patients) had follow-up longer than 12 months. A treatment change required 7.7 % subjects treated with ranibizumab, 20.5 % with pegaptanib and 22 % with PDT and verteporfin. Average BCVA of all patients at the beginning of primary treatment was 50.7 +- 3 letters and 43 +- 3.5 letters in 12th month (P<0.001). The mean decrease in BCVA was 7.7 +- 0.6 letters during the first 6 months of observation. During the next 6 months, no significant change occurred. The change of primary therapy was required on average after 6.5 +- 2.1 months. Conclusion. BCVA los was the most significantly decelerated in patients who received ranibizumab as a secondary therapy following unsuccessful treatment with pegaptanib sodium.
dcterms:title
Effects of Treatment Change in Patients with Neovascular age-related Macular Degeneration; Results from the Czech National Registry Effects of Treatment Change in Patients with Neovascular age-related Macular Degeneration; Results from the Czech National Registry
skos:prefLabel
Effects of Treatment Change in Patients with Neovascular age-related Macular Degeneration; Results from the Czech National Registry Effects of Treatment Change in Patients with Neovascular age-related Macular Degeneration; Results from the Czech National Registry
skos:notation
RIV/00179906:_____/12:10125172!RIV13-MZ0-00179906
n6:predkladatel
n11:ico%3A00179906
n4:aktivita
n7:V n7:S n7:I n7:N
n4:aktivity
I, N, S, V
n4:cisloPeriodika
4
n4:dodaniDat
n8:2013
n4:domaciTvurceVysledku
n17:6311520 n17:8228973 n17:4789385 n17:2737000
n4:druhVysledku
n13:J
n4:duvernostUdaju
n9:S
n4:entitaPredkladatele
n12:predkladatel
n4:idSjednocenehoVysledku
133509
n4:idVysledku
RIV/00179906:_____/12:10125172
n4:jazykVysledku
n18:eng
n4:klicovaSlova
photodynamic therapy with verteporfin; pegaptanib; ranibizumab; visual acuity; choroidal neovascular membrane; age-related macular degeneration
n4:klicoveSlovo
n5:photodynamic%20therapy%20with%20verteporfin n5:age-related%20macular%20degeneration n5:ranibizumab n5:pegaptanib n5:visual%20acuity n5:choroidal%20neovascular%20membrane
n4:kodStatuVydavatele
CZ - Česká republika
n4:kontrolniKodProRIV
[B1580263DE02]
n4:nazevZdroje
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, CzechoSK
n4:obor
n19:FF
n4:pocetDomacichTvurcuVysledku
4
n4:pocetTvurcuVysledku
10
n4:rokUplatneniVysledku
n8:2012
n4:svazekPeriodika
156
n4:tvurceVysledku
Kolář, Petr Rencová, Eva Chrapek, Oldřich Řehák, Jiří Rozsíval, Pavel Dusová, Jaroslava Kandrnal, Vít Studnička, Jan Pitrová, Šárka Dubská, Zora
n4:wos
000312983100013
s:issn
1213-8118
s:numberOfPages
6
n15:doi
10.5507/bp.2012.100